Overview

Effect of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) on the PK of Rosuvastatin in Healthy Participants

Status:
NOT_YET_RECRUITING

Trial end date:
2026-04-04

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the effect of multiple doses of vanzacaftor/tezacaftor/deutivacaftor (VNZ/TEZ/D-IVA) on the PK of rosuvastatin and the safety and tolerability of coadministration of VNZ/TEZ/D-IVA with rosuvastatin.

Phase:

PHASE1

Details

Lead Sponsor:

Vertex Pharmaceuticals Incorporated

Treatments:

deutivacaftor, tezacaftor , vanzacaftor
Rosuvastatin Calcium